Tags : Russia

RedHill Biopharma Reports the Submission of CTA for P-II/III Study

Shots: RedHill has submitted CTA with the Ministry of Health of the Russian Federation for a P-II/III clinical study evaluating Yeliva (opaganib, ABC294640)1 in patients hospitalized with severe COVID-19 and pneumonia The P-II/III study will assess opaganib vs placebo, on top of SOC and plans to enroll 270 patients with severe COVID-19 pneumonia requiring hospitalization […]Read More

AstraZeneca Divests Rights of Seroquel and Seroquel XR to Cheplapharm

Shots: AstraZeneca to receive $178M up front and up to $61M as sales-contingent payments while it continues to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition period. The transaction is expected to be closed in Q4’19 The divestiture will allow AstraZeneca to focus on its main therapeutic areas by reducing its […]Read More

Generium and Selexis Launch Eculizumab Biosimilar for Paroxysmal Nocturnal Hemoglobinuria

Shots: Generium’s biosimilar of Eculizumab is developed using Selexis’ SUREtechnology Platform which is based on Selexis SGE (Selexis Genetic Elements) consist of human DNA based element, controlling the chromatin across mammalian cells Eculizumab is a monoclonal IgG2/4 Ab developed as a fifth biosimilar SUREtechnology Platform involved in reduction of the destruction of red blood cells […]Read More

AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-III

Shots: The global P-III HARMONIZE involves assessing of Lokelma (5/10mg) vs PBO in 267 patients with hyperkalaemia in Japan, Korea, Taiwan and Russia across 47 locations P-III HARMONIZE Results: @48 hrs.: Achieved normokalaemia (mean K level 3.5-5.0 mEq/L) 93%; safety was consistent with previous trials. These results will support its registration in Japan, Korea, Taiwan […]Read More